NFKB1 and COVID-19: According to other studies, doxycycline may delay COVID-19 progression via anti-inflammatory activities, including regulating the NFκB pathway and inhibition of proinflammatory cytokine levels (IL-6, IL-1β, TNFα), measured during ARDS in severely ill COVID-19 patients [95].